GB202008961D0 - Pharmaceutical composition - Google Patents

Pharmaceutical composition

Info

Publication number
GB202008961D0
GB202008961D0 GBGB2008961.1A GB202008961A GB202008961D0 GB 202008961 D0 GB202008961 D0 GB 202008961D0 GB 202008961 A GB202008961 A GB 202008961A GB 202008961 D0 GB202008961 D0 GB 202008961D0
Authority
GB
United Kingdom
Prior art keywords
pharmaceutical composition
pharmaceutical
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2008961.1A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beckley Psytech Ltd
Original Assignee
Beckley Psytech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beckley Psytech Ltd filed Critical Beckley Psytech Ltd
Priority to GBGB2008961.1A priority Critical patent/GB202008961D0/en
Publication of GB202008961D0 publication Critical patent/GB202008961D0/en
Priority to GB2019241.5A priority patent/GB2596884B8/en
Priority to KR1020237001336A priority patent/KR20230024378A/en
Priority to JP2022576811A priority patent/JP2023530292A/en
Priority to CA3187020A priority patent/CA3187020A1/en
Priority to IL298871A priority patent/IL298871A/en
Priority to EP21735379.6A priority patent/EP3941583B9/en
Priority to PCT/GB2021/051476 priority patent/WO2021250435A1/en
Priority to EP23157604.2A priority patent/EP4279070A3/en
Priority to AU2021289147A priority patent/AU2021289147A1/en
Priority to BR112022025306A priority patent/BR112022025306A2/en
Priority to PCT/GB2021/051475 priority patent/WO2021250434A1/en
Priority to EP21735380.4A priority patent/EP3941904A1/en
Priority to CN202180055398.7A priority patent/CN116056762A/en
Priority to US17/660,981 priority patent/US11518743B2/en
Priority to US17/660,873 priority patent/US11518742B2/en
Priority to US17/817,548 priority patent/US11603353B2/en
Priority to US17/935,256 priority patent/US11680044B2/en
Priority to US18/162,976 priority patent/US20230348381A1/en
Priority to US18/310,822 priority patent/US20230382858A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
GBGB2008961.1A 2020-06-12 2020-06-12 Pharmaceutical composition Ceased GB202008961D0 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
GBGB2008961.1A GB202008961D0 (en) 2020-06-12 2020-06-12 Pharmaceutical composition
GB2019241.5A GB2596884B8 (en) 2020-06-12 2020-12-07 A pharmaceutical composition comprising a benzoate salt of 5-methoxy-N,N-dimethyltryptamine
CN202180055398.7A CN116056762A (en) 2020-06-12 2021-06-14 Compositions comprising benzoates of 5-methoxy-N, N-dimethyltryptamine
EP23157604.2A EP4279070A3 (en) 2020-06-12 2021-06-14 Composition comprising a benzoate salt of 5-methoxy-n,n-dimethyltryptamine
PCT/GB2021/051475 WO2021250434A1 (en) 2020-06-12 2021-06-14 Composition comprising a benzoate salt of 5-methoxy-n,n-dimethyltryptamine
CA3187020A CA3187020A1 (en) 2020-06-12 2021-06-14 Composition comprising a benzoate salt of 5-methoxy-n,n-dimethyltryptamine
IL298871A IL298871A (en) 2020-06-12 2021-06-14 Composition comprising a benzoate salt of 5-methoxy-n,n-dimethyltryptamine
EP21735379.6A EP3941583B9 (en) 2020-06-12 2021-06-14 Composition comprising a benzoate salt of 5-methoxy-n,n-dimethyltryptamine
PCT/GB2021/051476 WO2021250435A1 (en) 2020-06-12 2021-06-14 Pharmaceutical composition comprising 5-methoxy-n,n-dimethyltryptamine
KR1020237001336A KR20230024378A (en) 2020-06-12 2021-06-14 A composition comprising the benzoate salt of 5-methoxy-N,N-dimethyltryptamine
AU2021289147A AU2021289147A1 (en) 2020-06-12 2021-06-14 Composition comprising a benzoate salt of 5-methoxy-N,N-dimethyltryptamine
BR112022025306A BR112022025306A2 (en) 2020-06-12 2021-06-14 COMPOSITION COMPRISING A BENZOATE SALT OF 5-METHOXIN, N-DIMETHYLTRIPTAMINE
JP2022576811A JP2023530292A (en) 2020-06-12 2021-06-14 Compositions containing the benzoate salt of 5-methoxy-N,N-dimethyltryptamine
EP21735380.4A EP3941904A1 (en) 2020-06-12 2021-06-14 Pharmaceutical composition comprising 5-methoxy-n,n-dimethyltryptamine
US17/660,873 US11518742B2 (en) 2020-06-12 2022-04-27 Composition comprising a benzoate salt of 5-methoxy-N,N-dimethyltryptamine
US17/660,981 US11518743B2 (en) 2020-06-12 2022-04-27 Pharmaceutical composition comprising 5-methoxy-N,N-dimethyltryptamine
US17/817,548 US11603353B2 (en) 2020-06-12 2022-08-04 Composition comprising a benzoate salt of 5-methoxy-N,N-dimethyltryptamine
US17/935,256 US11680044B2 (en) 2020-06-12 2022-09-26 Pharmaceutical composition comprising 5-methoxy-n,n-dimethyltryptamine
US18/162,976 US20230348381A1 (en) 2020-06-12 2023-02-01 Composition comprising a benzoate salt of 5-methoxy-n,n-dimethyltryptamine
US18/310,822 US20230382858A1 (en) 2020-06-12 2023-05-02 Pharmaceutical composition comprising 5-methoxy-n,n-dimethyltryptamine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2008961.1A GB202008961D0 (en) 2020-06-12 2020-06-12 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
GB202008961D0 true GB202008961D0 (en) 2020-07-29

Family

ID=71835429

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB2008961.1A Ceased GB202008961D0 (en) 2020-06-12 2020-06-12 Pharmaceutical composition
GB2019241.5A Active GB2596884B8 (en) 2020-06-12 2020-12-07 A pharmaceutical composition comprising a benzoate salt of 5-methoxy-N,N-dimethyltryptamine

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB2019241.5A Active GB2596884B8 (en) 2020-06-12 2020-12-07 A pharmaceutical composition comprising a benzoate salt of 5-methoxy-N,N-dimethyltryptamine

Country Status (1)

Country Link
GB (2) GB202008961D0 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201907871D0 (en) 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
WO2021089872A1 (en) 2019-11-07 2021-05-14 Small Pharma Ltd Compounds
US11773062B2 (en) 2021-03-22 2023-10-03 Small Pharma Ltd Deuterated compounds
US20210378969A1 (en) 2020-06-02 2021-12-09 Small Pharma Ltd. Therapeutic solid dosage forms
JP2023530292A (en) 2020-06-12 2023-07-14 ベックリー・サイテック・リミテッド Compositions containing the benzoate salt of 5-methoxy-N,N-dimethyltryptamine
US11406619B2 (en) 2020-08-28 2022-08-09 Small Pharma Ltd Injectable formulations
US11660289B2 (en) 2020-12-01 2023-05-30 Small Pharma Ltd. Deuterated or partially deuterated N,N-dimethyltryptamine compounds
US11697638B2 (en) 2021-09-08 2023-07-11 Small Pharma Ltd 5-methoxy-N,N-dimethyltryptamine crystalline forms
GB202212116D0 (en) 2022-08-19 2022-10-05 Beckley Psytech Ltd Pharmaceutically acceptable salts and Compositions thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2363123A1 (en) * 2006-06-28 2011-09-07 Chelsea Therapeutics, Inc. Pharmaceutical compositions comprising droxidopa
EP2720536A4 (en) * 2011-06-16 2015-04-01 Harvard College Novel rodent control agents and uses thereof
US9073851B2 (en) * 2011-10-28 2015-07-07 Board Of Regents, The University Of Texas System Compositions and methods for treating cancer

Also Published As

Publication number Publication date
GB2596884B (en) 2022-09-21
GB2596884B8 (en) 2023-08-09
GB2596884A8 (en) 2023-08-09
GB202019241D0 (en) 2021-01-20
GB2596884A (en) 2022-01-12

Similar Documents

Publication Publication Date Title
GB202019241D0 (en) Pharmaceutical composition
IL304290A (en) Pharmaceutical composition
GB201911517D0 (en) Pharmaceutical composition
FI3908321T3 (en) Pharmaceutical composition
GB202208464D0 (en) Pharmaceutical composition
GB202109271D0 (en) Pharmaceutical composition
GB202108387D0 (en) Pharmaceutical composition
GB202107518D0 (en) Pharmaceutical composition
GB202105858D0 (en) Pharmaceutical composition
GB202105462D0 (en) Pharmaceutical composition
GB202105047D0 (en) Pharmaceutical composition
GB202105049D0 (en) Pharmaceutical composition
GB202104224D0 (en) Pharmaceutical composition
GB202102095D0 (en) Pharmaceutical composition
GB202102100D0 (en) Pharmaceutical composition
GB202101638D0 (en) Pharmaceutical composition
GB202101640D0 (en) Pharmaceutical composition
GB202101634D0 (en) Pharmaceutical composition
GB202101123D0 (en) Pharmaceutical composition
GB202100711D0 (en) Pharmaceutical composition
GB202020504D0 (en) Pharmaceutical composition
GB202019237D0 (en) Pharmaceutical composition
GB202018068D0 (en) Pharmaceutical composition
GB202012053D0 (en) Pharmaceutical composition
GB202012057D0 (en) Pharmaceutical composition

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)